Xenon Pharmaceuticals Stock Price, News & Analysis (NASDAQ:XENE)

$3.74 +0.04 (+1.08 %)
(As of 02/22/2018 04:00 PM ET)
Previous Close$3.70
Today's Range$3.61 - $3.75
52-Week Range$2.10 - $9.95
Volume25,851 shs
Average Volume52,615 shs
Market Capitalization$67.04 million
P/E Ratio-2.36
Dividend YieldN/A
Beta1.46

About Xenon Pharmaceuticals (NASDAQ:XENE)

Xenon Pharmaceuticals logoXenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically, it is intended to treat LPLD in patients with severe or multiple pancreatitis attacks, despite dietary fat restrictions. TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system. XEN901 is developed for the treatment of rare infantile epileptic encephalopathy and other forms of epilepsy. XEN1101, is a potassium channel modulator for the treatment of epilepsy. Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans.

Receive XENE News and Ratings via Email

Sign-up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:XENE
CUSIPN/A
Phone604-484-3300

Debt

Debt-to-Equity RatioN/A
Current Ratio14.75%
Quick Ratio14.75%

Price-To-Earnings

Trailing P/E Ratio-2.35534591194969
Forward P/E Ratio-2.51
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.80 million
Price / Sales37.40
Cash FlowN/A
Price / CashN/A
Book Value$3.57 per share
Price / Book1.05

Profitability

Trailing EPS($1.59)
Net Income$-22,990,000.00
Net Margins-4,268.70%
Return on Equity-53.33%
Return on Assets-50.07%

Miscellaneous

Employees94
Outstanding Shares18,000,000

Xenon Pharmaceuticals (NASDAQ:XENE) Frequently Asked Questions

What is Xenon Pharmaceuticals' stock symbol?

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc (NASDAQ:XENE) posted its quarterly earnings results on Thursday, November, 3rd. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.43) by $0.08. The biopharmaceutical company had revenue of $0.41 million for the quarter, compared to analysts' expectations of $0.40 million. Xenon Pharmaceuticals had a negative net margin of 4,268.70% and a negative return on equity of 53.33%. View Xenon Pharmaceuticals' Earnings History.

When will Xenon Pharmaceuticals make its next earnings announcement?

Xenon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March, 14th 2018. View Earnings Estimates for Xenon Pharmaceuticals.

Where is Xenon Pharmaceuticals' stock going? Where will Xenon Pharmaceuticals' stock price be in 2018?

2 equities research analysts have issued twelve-month price targets for Xenon Pharmaceuticals' stock. Their predictions range from $5.00 to $5.00. On average, they expect Xenon Pharmaceuticals' share price to reach $5.00 in the next twelve months. View Analyst Ratings for Xenon Pharmaceuticals.

What are Wall Street analysts saying about Xenon Pharmaceuticals stock?

Here are some recent quotes from research analysts about Xenon Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada. " (1/21/2018)
  • 2. Jefferies Group LLC analysts commented, "Several key ph.II readouts, XEN801 in acne (March) and TV-45070 in post-herpetic neuralgia (PHN) (mid-year), should provide sig. NT stock catalysts. Based on our analyses, our view is their acne and pain programs collectively could generate $1.5B cumulative future royalties/milestones if successful, and a valuation we believe overly discounts the promise of their pipeline and platform, we view reward/risk favorably. Assuming at Buy with $13 PT." (3/13/2017)

Who are some of Xenon Pharmaceuticals' key competitors?

Who are Xenon Pharmaceuticals' key executives?

Xenon Pharmaceuticals' management team includes the folowing people:

  • Michael M. Tarnow, Chairman of the Board (Age 71)
  • Ian C. Mortimer MBA., CPA., CMA., Chief Financial Officer, Chief Operating Officer (Age 39)
  • James R. Empfield, Senior Vice President - Drug Discovery
  • Robin Paul Sherrington Ph.D., Senior Vice President of Business and Corporate Development (Age 54)
  • Charles M. Cohen Ph.D., Vice President - Biology (Age 66)
  • Yigal Paul Goldberg M.B., ChB., Ph.D., Vice President of Clinical Development (Age 55)
  • Karen G. Corraini J.D., General Counsel and Corporate Secretary (Age 60)
  • Simon Neil Pimstone M.B., ChB., Ph.D., President, Chief Executive Officer, Director (Age 47)
  • Mohammad Azab, Director (Age 59)
  • Steven R Gannon, Director (Age 55)

Who owns Xenon Pharmaceuticals stock?

Xenon Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Sabby Management LLC (1.83%), Renaissance Technologies LLC (1.38%) and K2 Principal Fund L.P. (1.22%). Company insiders that own Xenon Pharmaceuticals stock include Bvf Partners L P/Il, Frank A Holler, Gary Patou, Ian Mortimer, James R Empfield, Michael R Hayden, Mohammad Azab, Raymond Winquist, Richard H Scheller, Simon N Pimstone, Steven Gannon and Value Fund L P Biotechnology. View Institutional Ownership Trends for Xenon Pharmaceuticals.

Who bought Xenon Pharmaceuticals stock? Who is buying Xenon Pharmaceuticals stock?

Xenon Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, K2 Principal Fund L.P. and Sabby Management LLC. Company insiders that have bought Xenon Pharmaceuticals stock in the last two years include Bvf Partners L P/Il, Gary Patou, Ian Mortimer, James R Empfield, Michael R Hayden, Mohammad Azab, Raymond Winquist, Richard H Scheller, Simon N Pimstone, Steven Gannon and Value Fund L P Biotechnology. View Insider Buying and Selling for Xenon Pharmaceuticals.

How do I buy Xenon Pharmaceuticals stock?

Shares of Xenon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Xenon Pharmaceuticals' stock price today?

One share of Xenon Pharmaceuticals stock can currently be purchased for approximately $3.74.

How big of a company is Xenon Pharmaceuticals?

Xenon Pharmaceuticals has a market capitalization of $67.04 million and generates $1.80 million in revenue each year. The biopharmaceutical company earns $-22,990,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Xenon Pharmaceuticals employs 94 workers across the globe.

How can I contact Xenon Pharmaceuticals?

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at 604-484-3300 or via email at [email protected]


MarketBeat Community Rating for Xenon Pharmaceuticals (XENE)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  148 (Vote Outperform)
Underperform Votes:  94 (Vote Underperform)
Total Votes:  242
MarketBeat's community ratings are surveys of what our community members think about Xenon Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Xenon Pharmaceuticals (NASDAQ:XENE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.00$5.00$8.17$12.50
Price Target Upside: 66.67% upside66.67% upside172.22% upside316.67% upside

Xenon Pharmaceuticals (NASDAQ:XENE) Consensus Price Target History

Price Target History for Xenon Pharmaceuticals (NASDAQ:XENE)

Xenon Pharmaceuticals (NASDAQ:XENE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/4/2017Jefferies GroupSet Price TargetBuy$5.00MediumView Rating Details
6/27/2017Canaccord GenuityReiterated RatingBuy$5.00LowView Rating Details
12/22/2016Bloom BurtonInitiated CoverageBuy$14.50N/AView Rating Details
10/21/2016Stifel NicolausInitiated CoverageBuy$18.00N/AView Rating Details
9/26/2016GuggenheimInitiated CoverageBuy -> Buy$20.00N/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Xenon Pharmaceuticals (NASDAQ:XENE) Earnings History and Estimates Chart

Earnings by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)

Xenon Pharmaceuticals (NASDAQ XENE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2018($0.11)N/AView Earnings Details
11/7/2017Q3 2017($0.08)($0.43)$6.52 million$0.26 millionViewN/AView Earnings Details
8/3/20176/30/2017($0.38)($0.41)$0.38 million$0.02 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.35)($0.43)$0.45 million$0.02 millionViewN/AView Earnings Details
3/8/201712/31/2016($0.42)($0.32)$0.40 million$0.38 millionViewListenView Earnings Details
11/3/2016Q316($0.43)($0.51)$0.40 million$0.41 millionViewListenView Earnings Details
8/3/2016Q216($0.48)($0.42)$0.50 million$0.41 millionViewN/AView Earnings Details
5/10/2016Q116($0.21)($0.23)$3.30 million$0.60 millionViewListenView Earnings Details
3/8/2016Q415($0.16)($0.27)$4.90 million$3.23 millionViewListenView Earnings Details
11/10/2015Q315($0.02)($0.27)$4.65 million$4.29 millionViewListenView Earnings Details
8/10/2015Q215($0.16)($0.07)$4.90 million$4.05 millionViewListenView Earnings Details
5/12/2015Q115$0.14($0.30)$4.65 million$4.00 millionViewListenView Earnings Details
3/12/2015Q4($0.09)$1.57$5.10 million$4.43 millionViewListenView Earnings Details
12/15/2014$0.41$1.69$5.00 million$13.19 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Xenon Pharmaceuticals (NASDAQ:XENE) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.49 EPS
Next Year EPS Consensus Estimate: $-1.67 EPS

Dividends

Dividend History for Xenon Pharmaceuticals (NASDAQ:XENE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Xenon Pharmaceuticals (NASDAQ XENE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.40%
Institutional Ownership Percentage: 54.48%
Insider Trades by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)
Institutional Ownership by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)

Xenon Pharmaceuticals (NASDAQ XENE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/15/2017Mohammad AzabDirectorBuy15,000$2.22$33,300.00View SEC Filing  
9/22/2017Mohammad AzabDirectorBuy10,000$2.95$29,500.0021,210View SEC Filing  
8/18/2017Mohammad AzabDirectorBuy6,335$2.90$18,371.5012,898View SEC Filing  
8/18/2017Raymond WinquistInsiderBuy1,000$3.00$3,000.001,000View SEC Filing  
8/15/2017Bvf Partners L P/IlMajor ShareholderBuy18,858$2.41$45,447.78View SEC Filing  
8/15/2017James R EmpfieldSVPBuy10,000$2.48$24,800.0010,000View SEC Filing  
8/15/2017Value Fund L P BiotechnologyInsiderBuy60,202$2.61$157,127.22View SEC Filing  
8/14/2017Bvf Partners L P/IlMajor ShareholderBuy41,344$2.70$111,628.80View SEC Filing  
8/14/2017Michael R HaydenDirectorBuy15,000$2.75$41,250.00161,187View SEC Filing  
8/11/2017Steven GannonDirectorBuy15,000$2.82$42,300.0015,000View SEC Filing  
8/10/2017Ian MortimerCFOBuy15,000$2.88$43,200.006,000View SEC Filing  
8/10/2017Richard H SchellerDirectorBuy7,000$2.85$19,950.007,000View SEC Filing  
8/10/2017Simon N PimstoneCEOBuy6,000$2.90$17,400.00217,847View SEC Filing  
8/8/2017Gary PatouDirectorBuy5,000$3.00$15,000.0012,028View SEC Filing  
6/27/2017Value Fund L P BiotechnologyInsiderBuy85,461$4.00$341,844.00View SEC Filing  
6/22/2017Value Fund L P BiotechnologyInsiderBuy20,411$4.00$81,644.00View SEC Filing  
6/19/2017Value Fund L P BiotechnologyInsiderBuy26,408$3.84$101,406.72View SEC Filing  
6/7/2017Value Fund L P BiotechnologyInsiderBuy358,698$3.81$1,366,639.38View SEC Filing  
12/15/2016Frank A HollerDirectorSell30,000$7.85$235,500.00115,869View SEC Filing  
8/19/2016Frank A HollerDirectorSell11,938$7.65$91,325.70145,869View SEC Filing  
8/18/2016Frank A HollerDirectorSell18,062$7.93$143,231.66169,006View SEC Filing  
6/24/2016Ian MortimerCFOBuy5,300$6.22$32,966.001,000View SEC Filing  
9/24/2015Y. Paul GoldbergVPSell22,149$8.88$196,683.126,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Xenon Pharmaceuticals (NASDAQ XENE) News Headlines

Source:
DateHeadline
Xenon Pharmaceuticals Inc (XENE) Expected to Post Quarterly Sales of $6.38 MillionXenon Pharmaceuticals Inc (XENE) Expected to Post Quarterly Sales of $6.38 Million
www.americanbankingnews.com - February 22 at 4:32 AM
-$0.11 EPS Expected for Xenon Pharmaceuticals Inc (XENE) This Quarter-$0.11 EPS Expected for Xenon Pharmaceuticals Inc (XENE) This Quarter
www.americanbankingnews.com - February 20 at 11:14 PM
BRIEF-Xenon Advances Second Proprietary Epilepsy Product Into Clinic With Initiation Of Xen901 Phase 1 Clinical TrialBRIEF-Xenon Advances Second Proprietary Epilepsy Product Into Clinic With Initiation Of Xen901 Phase 1 Clinical Trial
www.reuters.com - February 20 at 5:45 PM
Xenon Pharmaceuticals Advances Second Proprietary Epilepsy Product into the Clinic with Initiation of XEN901 Phase 1 Clinical TrialXenon Pharmaceuticals Advances Second Proprietary Epilepsy Product into the Clinic with Initiation of XEN901 Phase 1 Clinical Trial
finance.yahoo.com - February 20 at 5:45 PM
Xenon Pharmaceuticals (XENE) Upgraded at ValuEngineXenon Pharmaceuticals (XENE) Upgraded at ValuEngine
www.americanbankingnews.com - February 4 at 10:14 AM
Head to Head Review: Xenon Pharmaceuticals (XENE) & Bioverativ (BIVV)Head to Head Review: Xenon Pharmaceuticals (XENE) & Bioverativ (BIVV)
www.americanbankingnews.com - February 3 at 11:18 PM
Xenon Pharmaceuticals (XENE) Stock Rating Upgraded by Zacks Investment ResearchXenon Pharmaceuticals (XENE) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - January 21 at 6:34 AM
Zacks: Analysts Expect Xenon Pharmaceuticals Inc (XENE) Will Post Quarterly Sales of $6.38 MillionZacks: Analysts Expect Xenon Pharmaceuticals Inc (XENE) Will Post Quarterly Sales of $6.38 Million
www.americanbankingnews.com - January 20 at 6:28 PM
Xenon Pharmaceuticals Inc (XENE) Expected to Post Earnings of -$0.11 Per ShareXenon Pharmaceuticals Inc (XENE) Expected to Post Earnings of -$0.11 Per Share
www.americanbankingnews.com - January 18 at 1:42 AM
Xenon Pharmaceuticals Outlines Key Milestones for 2018Xenon Pharmaceuticals Outlines Key Milestones for 2018
finance.yahoo.com - January 8 at 10:41 AM
$6.38 Million in Sales Expected for Xenon Pharmaceuticals Inc (XENE) This Quarter$6.38 Million in Sales Expected for Xenon Pharmaceuticals Inc (XENE) This Quarter
www.americanbankingnews.com - January 3 at 3:00 PM
 Analysts Expect Xenon Pharmaceuticals Inc. (XENE) Will Announce Quarterly Sales of $6.38 Million Analysts Expect Xenon Pharmaceuticals Inc. (XENE) Will Announce Quarterly Sales of $6.38 Million
www.americanbankingnews.com - December 17 at 8:48 AM
 Analysts Anticipate Xenon Pharmaceuticals Inc. (XENE) Will Announce Earnings of -$0.11 Per Share Analysts Anticipate Xenon Pharmaceuticals Inc. (XENE) Will Announce Earnings of -$0.11 Per Share
www.americanbankingnews.com - December 15 at 1:34 PM
Xenon Pharmaceuticals (XENE) Says Positive Preclinical Data from its XEN901 Epilepsy Program to be Presented at AESXenon Pharmaceuticals (XENE) Says Positive Preclinical Data from its XEN901 Epilepsy Program to be Presented at AES
www.streetinsider.com - December 6 at 10:47 AM
Xenon Pharmaceuticals (XENE) Says Positive Preclinical Data from ... - StreetInsider.comXenon Pharmaceuticals (XENE) Says Positive Preclinical Data from ... - StreetInsider.com
www.streetinsider.com - December 5 at 12:14 PM
Positive Preclinical Data from Xenon’s XEN901 Epilepsy Program to be Presented at the 71st American Epilepsy Society Annual MeetingPositive Preclinical Data from Xenon’s XEN901 Epilepsy Program to be Presented at the 71st American Epilepsy Society Annual Meeting
finance.yahoo.com - December 4 at 4:26 PM
 Analysts Anticipate Xenon Pharmaceuticals Inc. (XENE) Will Announce Quarterly Sales of $6.38 Million Analysts Anticipate Xenon Pharmaceuticals Inc. (XENE) Will Announce Quarterly Sales of $6.38 Million
www.americanbankingnews.com - November 29 at 11:56 AM
Appili Therapeutics Appoints Seasoned Biotech Executive Ian C. Mortimer to its BoardAppili Therapeutics Appoints Seasoned Biotech Executive Ian C. Mortimer to its Board
www.businesswire.com - November 28 at 11:34 AM
Head to Head Review: Ardelyx (ARDX) & Xenon Pharmaceuticals (XENE)Head to Head Review: Ardelyx (ARDX) & Xenon Pharmaceuticals (XENE)
www.americanbankingnews.com - November 18 at 11:34 PM
Xenon Pharmaceuticals Inc. (XENE) Director Acquires $33,300.00 in StockXenon Pharmaceuticals Inc. (XENE) Director Acquires $33,300.00 in Stock
www.americanbankingnews.com - November 16 at 9:24 PM
FY2017 EPS Estimates for Xenon Pharmaceuticals Inc. (XENE) Lowered by Jefferies GroupFY2017 EPS Estimates for Xenon Pharmaceuticals Inc. (XENE) Lowered by Jefferies Group
www.americanbankingnews.com - November 10 at 12:26 PM
FDA Nod For COLL, INGN Ups View, Positive News Dimmed By Earnings Miss At KERXFDA Nod For COLL, INGN Ups View, Positive News Dimmed By Earnings Miss At KERX
www.rttnews.com - November 9 at 10:18 AM
Xenon Pharmaceuticals to Present at the Stifel 2017 Healthcare ConferenceXenon Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference
finance.yahoo.com - November 9 at 10:18 AM
Xenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017Xenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
finance.yahoo.com - November 9 at 10:18 AM
Jefferies Group Analysts Reduce Earnings Estimates for Xenon Pharmaceuticals Inc. (XENE)Jefferies Group Analysts Reduce Earnings Estimates for Xenon Pharmaceuticals Inc. (XENE)
www.americanbankingnews.com - November 9 at 9:34 AM
Xenon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate UpdateXenon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 7 at 7:12 PM
Xenon Pharmaceuticals reports 3Q lossXenon Pharmaceuticals reports 3Q loss
finance.yahoo.com - November 7 at 7:12 PM
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2017 Financial Results and Provide Corporate UpdateXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2017 Financial Results and Provide Corporate Update
finance.yahoo.com - November 2 at 11:48 AM
Xenon Pharmaceuticals (XENE) & Its Competitors Financial AnalysisXenon Pharmaceuticals (XENE) & Its Competitors Financial Analysis
www.americanbankingnews.com - October 26 at 9:30 AM
Xenon Pharmaceuticals Inc. (XENE) Set to Announce Quarterly Earnings on WednesdayXenon Pharmaceuticals Inc. (XENE) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 25 at 7:28 AM
$6.52 Million in Sales Expected for Xenon Pharmaceuticals Inc. (XENE) This Quarter$6.52 Million in Sales Expected for Xenon Pharmaceuticals Inc. (XENE) This Quarter
www.americanbankingnews.com - October 21 at 1:52 AM
Zacks: Brokerages Anticipate Xenon Pharmaceuticals Inc. (XENE) Will Post Earnings of -$0.08 Per ShareZacks: Brokerages Anticipate Xenon Pharmaceuticals Inc. (XENE) Will Post Earnings of -$0.08 Per Share
www.americanbankingnews.com - October 19 at 10:30 PM
Xenon Pharmaceuticals Announces Initiation of XEN1101 Phase 1 Clinical TrialXenon Pharmaceuticals Announces Initiation of XEN1101 Phase 1 Clinical Trial
finance.yahoo.com - October 17 at 9:24 AM
Critical Analysis: Xenon Pharmaceuticals (XENE) & Its PeersCritical Analysis: Xenon Pharmaceuticals (XENE) & Its Peers
www.americanbankingnews.com - October 12 at 12:56 PM
Xenon Pharmaceuticals Inc. (XENE) Upgraded at Zacks Investment ResearchXenon Pharmaceuticals Inc. (XENE) Upgraded at Zacks Investment Research
www.americanbankingnews.com - October 5 at 9:50 AM
Xenon Pharmaceuticals Inc. (XENE) Expected to Announce Quarterly Sales of $6.52 MillionXenon Pharmaceuticals Inc. (XENE) Expected to Announce Quarterly Sales of $6.52 Million
www.americanbankingnews.com - October 3 at 11:40 AM
-$0.08 EPS Expected for Xenon Pharmaceuticals Inc. (XENE) This Quarter-$0.08 EPS Expected for Xenon Pharmaceuticals Inc. (XENE) This Quarter
www.americanbankingnews.com - October 1 at 4:30 AM
Mohammad Azab Purchases 10,000 Shares of Xenon Pharmaceuticals Inc. (XENE) StockMohammad Azab Purchases 10,000 Shares of Xenon Pharmaceuticals Inc. (XENE) Stock
www.americanbankingnews.com - September 25 at 7:36 PM
Contrasting Xenon Pharmaceuticals (XENE) and Aileron Therapeutics (ALRN)Contrasting Xenon Pharmaceuticals (XENE) and Aileron Therapeutics (ALRN)
www.americanbankingnews.com - September 23 at 4:20 PM
Xenon Pharmaceuticals Inc. (XENE) Receives Consensus Rating of "Buy" from BrokeragesXenon Pharmaceuticals Inc. (XENE) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - September 23 at 9:18 AM
Xenon Pharmaceuticals Inc. (XENE) Receives Average Rating of "Buy" from AnalystsXenon Pharmaceuticals Inc. (XENE) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - August 29 at 9:06 AM
Xenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017Xenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 25 at 12:52 PM
Mohammad Azab Purchases 6,335 Shares of Xenon Pharmaceuticals Inc. (XENE) StockMohammad Azab Purchases 6,335 Shares of Xenon Pharmaceuticals Inc. (XENE) Stock
www.americanbankingnews.com - August 21 at 8:32 PM
James R. Empfield Acquires 10,000 Shares of Xenon Pharmaceuticals Inc. (XENE) StockJames R. Empfield Acquires 10,000 Shares of Xenon Pharmaceuticals Inc. (XENE) Stock
www.americanbankingnews.com - August 17 at 8:52 PM
Gainers & Losers Of Aug.16: XENE, JNCE, MYOK, ADMS, LIFE...Gainers & Losers Of Aug.16: XENE, JNCE, MYOK, ADMS, LIFE...
www.finanznachrichten.de - August 17 at 9:33 AM
Xenon Pharmaceuticals Inc. (XENE) Major Shareholder Purchases $45,447.78 in StockXenon Pharmaceuticals Inc. (XENE) Major Shareholder Purchases $45,447.78 in Stock
www.americanbankingnews.com - August 16 at 9:36 PM
Xenon Pharmaceuticals Inc. (XENE) Major Shareholder Buys $111,628.80 in StockXenon Pharmaceuticals Inc. (XENE) Major Shareholder Buys $111,628.80 in Stock
www.americanbankingnews.com - August 16 at 9:14 PM
Xenon Pharmaceuticals Inc. (XENE) Insider Buys $157,127.22 in StockXenon Pharmaceuticals Inc. (XENE) Insider Buys $157,127.22 in Stock
www.americanbankingnews.com - August 16 at 8:46 PM
Xenon Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate UpdateXenon Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 15 at 9:08 PM
Insider Buying: Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Director Buys 7,000 Shares of StockInsider Buying: Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Director Buys 7,000 Shares of Stock
www.americanbankingnews.com - August 15 at 12:16 AM

SEC Filings

Xenon Pharmaceuticals (NASDAQ:XENE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Xenon Pharmaceuticals (NASDAQ:XENE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Xenon Pharmaceuticals (NASDAQ XENE) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.